These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24313873)

  • 1. Moxifloxacin dosing in post-bariatric surgery patients.
    Colin P; Eleveld DJ; Struys MM; T'Jollyn H; Bortel LM; Ruige J; De Waele J; Van Bocxlaer J; Boussery K
    Br J Clin Pharmacol; 2014 Jul; 78(1):84-93. PubMed ID: 24313873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections.
    Wicha SG; Haak T; Zink K; Kees F; Kloft C; Kees MG
    J Clin Pharmacol; 2015 Jun; 55(6):639-46. PubMed ID: 25600294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K; Hardlei TF; Brock B; Jensen-Fangel S; Kragh Thomsen M; Petersen E; Kreilgaard M
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents.
    Chidambaran V; Venkatasubramanian R; Sadhasivam S; Esslinger H; Cox S; Diepstraten J; Fukuda T; Inge T; Knibbe CAJ; Vinks AA
    Paediatr Anaesth; 2015 Sep; 25(9):911-923. PubMed ID: 25975390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
    Nielsen EI; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4619-30. PubMed ID: 21807983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice.
    Wicha SG; Mundkowski RG; Klock A; Hopt UT; Drewelow B; Kloft C; Wellner UF; Keck T; Wittel UA
    J Clin Pharmacol; 2019 Oct; 59(10):1405-1414. PubMed ID: 31111505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study.
    Carral N; Lukas JC; Oteo I; Suarez E
    Int J Antimicrob Agents; 2015 Jan; 45(1):79-83. PubMed ID: 25450804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of prophylactic cefoxitin in elective bariatric surgery patients: a prospective monocentric study.
    Novy E; Liu X; Hernández-Mitre MP; Belveyre T; Scala-Bertola J; Roberts JA; Parker SL
    Anaesth Crit Care Pain Med; 2024 Jun; 43(3):101376. PubMed ID: 38494157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.
    Miranda Bastos AC; Vandecasteele SJ; Spinewine A; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2018 Jun; 73(6):1630-1638. PubMed ID: 29579214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients.
    Zhu L; Wang N; Yang W; Zhang Y; Zhao X; Ji S
    J Infect Chemother; 2014 Oct; 20(10):621-6. PubMed ID: 25000831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
    Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.
    Alqahtani SA; Alsultan AS; Alqattan HM; Eldemerdash A; Albacker TB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
    Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
    Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.